NDAORALTABLET
Approved
Jul 2024
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 2h ago · AI intelligence enriched 2h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VOQUEZNA (vonoprazan fumarate) is an oral potassium-competitive acid blocker (KCAB) approved in July 2024 for acid-related gastrointestinal conditions. It represents a new mechanism class distinct from proton pump inhibitors (PPIs), offering faster onset and potentially superior efficacy in acid suppression. The drug targets patients requiring reliable gastric pH control for ulcer healing and GERD management.
Growth
Early-stage growth product with competitive pressure at 30%, indicating moderate market headwinds but opportunity for teams building market share in a newly launched therapeutic class.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Study to Evaluate the Bioequivalence of Vonopzan Tablet 20mg(Vonoprazan Fumarate) and Vocinti Tablet 20mg in Healthy Adult Subjects.
Started Oct 2023
30 enrolled
Gastric Ulcer
Career Relevance
VOQUEZNA represents a rare opportunity to join a newly launched specialty medicine product with a differentiated mechanism in a large, established market. Early-stage team building and the need to establish clinical relevance against entrenched competitors offer meaningful career exposure to product lifecycle management, market access, and physician education.
Intern
Worked on VOQUEZNA at Phathom Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.